Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIT: Mepolizumab in Eosinophilic Chronic Rhinosinusitis
jRCT2031200306Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic chronic rhinosinusitis (ECRS) and asthma comparing Mepolizumab arm with Placebo arm (2 arms). Primary endpoints: Change from baseline in total endoscopic nasal polyp score at Week 52 and Change from baseline in mean nasal obstruction visual analogue scale (VAS) score. Started Feb 2021; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)eosinophilic chronic rhinosinusitis (ECRS)asthma
Beyond the preview
Go deeper on jRCT2031200306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200306.